- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Evommune, Inc. GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
| Mo | Evommune Aktie: H.C. Wainwright bestätigt "Neutral"-Rating | 1 | Investing.com Deutsch | ||
| Mo | Evommune stock: H.C. Wainwright reiterates Neutral rating | 1 | Investing.com | ||
| 30.07. | Evommune doses first patient in migraine prevention trial | 1 | Investing.com | ||
| 30.07. | Evommune startet Phase-2b-Studie zur Migräneprophylaxe mit EVO756 | 1 | Investing.com Deutsch | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 30.07. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.06. | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal | 1 | Zacks | ||
| 30.06. | Evommune stock downgraded by H.C. Wainwright after trial failure | 2 | Investing.com | ||
| 29.06. | Studien-Fehlschlag schickt Evommune Aktie auf Talfahrt | 7 | Investing.com Deutsch | ||
| 29.06. | Evommune's Skin Disorder Study Falls Short | 3 | Benzinga.com | ||
| 29.06. | Raymond James stuft Evommune nach gescheiterter Studie herab | - | Investing.com Deutsch | ||
| 29.06. | Raymond James cuts Evommune stock rating on trial miss | 2 | Investing.com | ||
| 29.06. | William Blair stuft Evommune Aktie auf 'Market Perform' herab | 2 | Investing.com Deutsch | ||
| 29.06. | Evommune stock rating cut to Market Perform by William Blair | 1 | Investing.com | ||
| 29.06. | Evommune's phase 2b trial flops, ending challenge to Novartis in hives | 12 | FierceBiotech | ||
| 29.06. | Evommune drops on phase 2 data for EVO756 in urticaria | 3 | Seeking Alpha | ||
| 29.06. | Evommune's EVO756 fails phase 2b trial in chronic urticaria | 3 | Investing.com | ||
| 29.06. | Evommune, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 02.06. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | H.C. Wainwright reiterates Evommune stock rating on trial progress | 1 | Investing.com |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,207 | +5,08 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| ATAIBECKLEY | 6,250 | -0,79 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,833 | -3,48 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,340 | +3,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,000 | +2,52 % | DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum | ||
| CEL-SCI | 1,500 | +2,74 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| CYTOKINETICS | 66,28 | -0,12 % | Cytokinetics, Incorporated: Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | MYQORZO- (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,098 | +0,27 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen | |
| CURIS | 3,405 | 0,00 % | Curis, Inc.: Curis Doses First Five Patients in TakeAim CLL Study | LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,929 | +0,83 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen |
EVOMMUNE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,045 (+0,32 %) liegt der Kurs bei 14,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.